Protagonist Therapeutics, Inc. (PTGX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
PTGX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PTGX Revenue Analysis (2014–2025)
As of February 28, 2026, Protagonist Therapeutics, Inc. (PTGX) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -122.6% year-over-year. The most recent quarter (Q4 2025) recorded $-38,579,000 in revenue, down 918.7% sequentially.
Looking at the longer-term picture, PTGX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $434.4 million in 2024.
Revenue diversification analysis shows PTGX's business is primarily driven by Development Services (100%). With over half of revenue concentrated in Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY), PTGX has underperformed the peer group in terms of revenue growth. Compare PTGX vs ARGX →
Peer Comparison
Compare PTGX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PTGXCurrent | $0 | -122.6% | - | - | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $-158,127,000 | - |
| 2024 | $434.4M | +624.1% | $434.4M | 100.0% | $252.8M | 58.2% |
| 2023 | $60.0M | +125.7% | $60.0M | 100.0% | $-93,652,000 | -156.1% |
| 2022 | $26.6M | -2.8% | $26.6M | 100.0% | $-131,373,000 | -494.2% |
| 2021 | $27.4M | -4.4% | $27.4M | 100.0% | $-125,845,000 | -460.0% |
| 2020 | $28.6M | +12293.1% | $28.6M | 100.0% | $-64,516,000 | -225.4% |
| 2019 | $231K | -99.3% | $231K | 100.0% | $-80,521,000 | -34857.6% |
| 2018 | $30.9M | +54.1% | $30.9M | 100.0% | $-42,269,000 | -136.7% |
| 2017 | $20.1M | - | $20.1M | 100.0% | $-37,897,000 | -188.9% |
| 2016 | $0 | - | $-317,000 | - | $-32,666,000 | - |
See PTGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTGX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PTGX vs AGIO
See how PTGX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PTGX's revenue growth accelerating or slowing?
PTGX revenue declined -122.6% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is PTGX's long-term revenue growth rate?
Protagonist Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -122.6% is below this long-term average.
How is PTGX's revenue distributed by segment?
PTGX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.